Vaccine on goodinfo.net Daily https://goodinfo.net/en/tags/vaccine/ goodinfo.net daily curated global news: AI, tech, finance, and world affairs. Hugo -- gohugo.io en goodinfo.net Fri, 22 May 2026 22:25:00 +0800 UK Scientists Developing Ebola Vaccine Ready for Trials in Months https://goodinfo.net/en/posts/health/uk-ebola-vaccine-trials-months-may-20260522/ Fri, 22 May 2026 22:25:00 +0800 goodinfo.net https://goodinfo.net/en/posts/health/uk-ebola-vaccine-trials-months-may-20260522/ UK scientists are developing a vaccine for the current Ebola outbreak in the Democratic Republic of Congo, with clinical trials expected to begin within months. The outbreak involves the rare Bundibugyo species of Ebola, which kills approximately one-third of those infected and has no approved vaccine. The WHO has upgraded its risk assessment, saying the outbreak is “spreading rapidly.” In eastern DR Congo, angry crowds burned medical tents after being prevented from burying the body of a suspected Ebola victim, highlighting community resistance to containment measures. UK scientists are developing a vaccine for the current Ebola outbreak in the Democratic Republic of Congo, with clinical trials expected to begin within months.

The outbreak involves the rare Bundibugyo species of Ebola, which kills approximately one-third of those infected and has no approved vaccine. The WHO has upgraded its risk assessment, saying the outbreak is “spreading rapidly.”

In eastern DR Congo, angry crowds burned medical tents after being prevented from burying the body of a suspected Ebola victim, highlighting community resistance to containment measures.

If successful, the UK-developed vaccine would become a critical tool against the Bundibugyo strain. Vaccines for the more common Zaire strain have proven effective in past outbreaks, but Bundibugyo vaccine development remains in early stages.

]]> health EbolavaccineUKscienceclinical-trial [Brief] WHO Warns Ebola Vaccine Could Take Nine Months as Death Toll Rises https://goodinfo.net/en/posts/health/ebola-vaccine-nine-months-who-may-20260521/ Thu, 21 May 2026 09:54:00 +0800 goodinfo.net https://goodinfo.net/en/posts/health/ebola-vaccine-nine-months-who-may-20260521/ The World Health Organization (WHO) has warned that a vaccine for the current Ebola outbreak could take up to nine months to develop, as the death toll continues to rise. The Washington Post previously reported that the White House had resisted letting an Ebola-infected doctor return to the US for treatment, sparking controversy. The outbreak is primarily spreading across African regions, with the international community ramping up aid efforts. Sources: BBC, Washington Post The World Health Organization (WHO) has warned that a vaccine for the current Ebola outbreak could take up to nine months to develop, as the death toll continues to rise. The Washington Post previously reported that the White House had resisted letting an Ebola-infected doctor return to the US for treatment, sparking controversy. The outbreak is primarily spreading across African regions, with the international community ramping up aid efforts.

Sources: BBC, Washington Post

]]> health EbolaWHOVaccinePublic Health [Flash] Moderna Stock Surges 14% on Hantavirus Vaccine Prospect https://goodinfo.net/en/posts/finance/moderna-stock-surges-hantavirus-vaccine-may-2026/ Sat, 09 May 2026 21:45:00 +0000 goodinfo.net https://goodinfo.net/en/posts/finance/moderna-stock-surges-hantavirus-vaccine-may-2026/ [Flash] Moderna Stock Surges 14% on Hantavirus Vaccine Prospect Moderna (MRNA) shares jumped 14% as investors reacted positively to the company’s hantavirus vaccine development. The surge comes amid global attention on the hantavirus cruise ship outbreak, with investors optimistic about the vaccine’s commercial potential. Analysts advise monitoring clinical trial progress. Source: Google News [Flash] Moderna Stock Surges 14% on Hantavirus Vaccine Prospect

Moderna (MRNA) shares jumped 14% as investors reacted positively to the company’s hantavirus vaccine development. The surge comes amid global attention on the hantavirus cruise ship outbreak, with investors optimistic about the vaccine’s commercial potential. Analysts advise monitoring clinical trial progress.

Source: Google News

]]> ModernaVaccineHantavirusStocks